Compare ORMP & SY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORMP | SY |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 218.8M |
| IPO Year | 2010 | 2018 |
| Metric | ORMP | SY |
|---|---|---|
| Price | $4.24 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 155.4K | ★ 204.0K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 6.51% | 0.91% |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | $38.64 |
| Revenue Next Year | N/A | $30.63 |
| P/E Ratio | $4.73 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $1.98 | $1.28 |
| 52 Week High | $5.19 | $5.35 |
| Indicator | ORMP | SY |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 69.96 |
| Support Level | $3.91 | $1.68 |
| Resistance Level | $4.22 | $3.34 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 46.37 | 80.47 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
So-Young International Inc is an aesthetic treatment platform in China connecting consumers with online services and offline treatments. Its online platform operates across multiple access points, including mobile app, Weixin mini program, and soyoung.com website, where both consumers and aesthetic practitioners can access media content, an engaging social community and a transparent reservation system. The company has four reportable segments: Aesthetic treatment services group, Platform service group, Wuhan Miracle, and Others. The majority of revenue is derived from the Platform service group, which generates revenue by providing information services and reservation services. All the company's revenues are derived from within the PRC.